Previous close | 85.70 |
Open | N/A |
Bid | 124.00 |
Ask | 130.70 |
Strike | 895.00 |
Expiry date | 2024-11-15 |
Day's range | 85.70 - 85.70 |
Contract range | N/A |
Volume | |
Open interest | 2 |
When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose...
There hasn't been a new COPD treatment in years. But Regeneron stock analysts are closely watching a pair of key FDA decisions.
Regeneron stock joined the 1,000-club this month as enthusiasm grows for its blockbuster drug, Dupixent, in COPD treatment.